1
|
Wakley AA, McBride AA, Vaughn LK, Craft RM. Cyclic ovarian hormone modulation of supraspinal Δ9-tetrahydrocannabinol-induced antinociception and cannabinoid receptor binding in the female rat. Pharmacol Biochem Behav 2014; 124:269-77. [DOI: 10.1016/j.pbb.2014.06.007] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/23/2014] [Revised: 05/20/2014] [Accepted: 06/10/2014] [Indexed: 10/25/2022]
|
2
|
Oliviero A, Arevalo-Martin A, Rotondi M, García-Ovejero D, Mordillo-Mateos L, Lozano-Sicilia A, Panyavin I, Chiovato L, Aguilar J, Foffani G, Di Lazzaro V, Molina-Holgado E. CB1 receptor antagonism/inverse agonism increases motor system excitability in humans. Eur Neuropsychopharmacol 2012; 22:27-35. [PMID: 21571507 DOI: 10.1016/j.euroneuro.2011.04.004] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/09/2010] [Revised: 03/14/2011] [Accepted: 04/17/2011] [Indexed: 10/18/2022]
Abstract
CB1 receptor is highly expressed in cerebral structures related to motor control, such as motor cortex, basal ganglia and cerebellum. In the spinal cord, the expression of CB1 receptors has also been observed in ventral motor neurons, interneurons and primary afferents, i.e., in the cells that may be part of the circuits involved in motor control. It is known that the antagonist/inverse agonist of CB1 receptors Rimonabant penetrates the blood-brain barrier and produces a broad range of central psychoactive effects in humans. Based on the occurrence of central effects in humans treated with Rimonabant and on the location of CB1 receptors, we hypothesized that the application of Rimonabant can also affect the motor system. We tested the effects of a single dose of 20mg of Rimonabant on the excitability of motor cortex and of spinal motor neurons in order to detect a possible drug action on motor system at cortical and spinal levels. For this purpose we use classical protocols of transcranial magnetic and electrical stimulation (TMS and TES). Single and paired pulse TMS and TES were used to assess a number of parameters of cortical inhibition and cortical excitability as well as of the excitability of spinal motor neurons. We demonstrated that a single oral dose of 20mg of Rimonabant can increase motor system excitability at cortical and spinal levels. This opens new avenues to test the CB1R antagonists/inverse agonists for the treatment of a number of neurological dysfunctions in which can be useful to increase the excitability levels of motor system. Virtually all the disorders characterized by a reduced output of the motor cortex can be included in the list of the disorders that can be treated using CB1 antagonists/reverse agonists (e.g. stroke, traumatic brain injury, spinal cord injury, multiple sclerosis, fatigue syndromes, parkinsonisms, etc.).
Collapse
Affiliation(s)
- A Oliviero
- FENNSI Group, Hospital Nacional de Parapléjicos, SESCAM, Toledo, Spain.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Pava MJ, Blake EM, Green ST, Mizroch BJ, Mulholland PJ, Woodward JJ. Tolerance to cannabinoid-induced behaviors in mice treated chronically with ethanol. Psychopharmacology (Berl) 2012; 219:137-47. [PMID: 21701813 PMCID: PMC3249519 DOI: 10.1007/s00213-011-2387-0] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/05/2011] [Accepted: 06/12/2011] [Indexed: 01/30/2023]
Abstract
RATIONALE Chronic ethanol (EtOH) treatment decreases the motor-impairing effects of cannabinoids and downregulates the cannabinoid type 1 (CB1) receptor. However, these studies have been limited to measures of ataxia and analysis of CB1 expression from whole-brain or hippocampal preparations. OBJECTIVE To more fully assess the interactions between ethanol and cannabinoids, a tetrad of four well-characterized cannabinoid-induced behaviors (hypolocomotion, antinociception, hypothermia, and catalepsy) was measured in mice following EtOH treatment. Additionally, immunoblotting assessed CB1 protein in tissue from nine brain regions associated with these behaviors and the addiction neurocircuitry. MATERIALS AND METHODS Male C57Bl/6J mice were administered EtOH (0, 2, or 4 g/kg; intraperitoneally (i.p.)) twice daily for 10 days. Tetrad behaviors induced by the CB1 agonist WIN 55212-2 (3 mg/kg, i.p.) were measured in subjects 1 or 10 days following the last EtOH injection. In a separate group of animals, tissue was collected at the same time points for immunoblot analysis. RESULTS EtOH-treated mice were less sensitive to the hypothermic, hypolocomotive, and antinociceptive effects of WIN, and this effect reversed to control levels over a 10-day abstinence period. EtOH treatment did not affect WIN-induced catalepsy. CB1 protein expression was significantly altered in several brain areas including the hypothalamus, periaqueductal gray, ventral tegmental area, and cerebellum. CONCLUSIONS These results show that chronic EtOH treatment significantly affects the behavioral sensitivity to cannabinoid drugs and alters CB1 expression in several brain regions. Furthermore, these effects are selective as some behaviors and brain regions display an altered response while others do not.
Collapse
Affiliation(s)
- Matthew J. Pava
- Department of Neurosciences, Medical University of South Carolina, Charleston, SC
- Charleston Alcohol Research Center, Medical University of South Carolina, Charleston, SC
| | - Emily M. Blake
- Program in Neuroscience, College of Charleston, Charleston, SC
| | | | | | - Patrick J. Mulholland
- Department of Neurosciences, Medical University of South Carolina, Charleston, SC
- Charleston Alcohol Research Center, Medical University of South Carolina, Charleston, SC
| | - John J. Woodward
- Department of Neurosciences, Medical University of South Carolina, Charleston, SC
- Charleston Alcohol Research Center, Medical University of South Carolina, Charleston, SC
| |
Collapse
|
4
|
Dimitrov EL, Petrus E, Usdin TB. Tuberoinfundibular peptide of 39 residues (TIP39) signaling modulates acute and tonic nociception. Exp Neurol 2010; 226:68-83. [PMID: 20696160 DOI: 10.1016/j.expneurol.2010.08.004] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2010] [Revised: 07/26/2010] [Accepted: 08/02/2010] [Indexed: 11/19/2022]
Abstract
Tuberoinfundibular peptide of 39 residues (TIP39) synthesizing neurons at the caudal border of the thalamus and in the lateral pons project to areas rich in its receptor, the parathyroid hormone 2 receptor (PTH2R). These areas include many involved in processing nociceptive information. Here we examined the potential role of TIP39 signaling in nociception using a PTH2R antagonist (HYWH) and mice with deletion of TIP39's coding sequence or PTH2R null mutation. Intracerebroventricular (icv) infusion of HYWH significantly inhibited nociceptive responses in tail-flick and hot-plate tests and attenuated the nociceptive response to hindpaw formalin injection. TIP39-KO and PTH2R-KO had increased response latency in the 55°C hot-plate test and reduced responses in the hindpaw formalin test. The tail-flick test was not affected in either KO line. Thermal hypoalgesia in KO mice was dose-dependently reversed by systemic administration of the cannabinoid receptor 1 (CB1) antagonist rimonabant, which did not affect nociception in wild-type (WT). Systemic administration of the cannabinoid agonist CP 55,940 did not affect nociception in KO mice at a dose effective in WT. WT mice administered HYWH icv, and both KOs, had significantly increased stress-induced analgesia (SIA). Rimonabant blocked the increased SIA in TIP39-KO, PTH2R-KO or after HYWH infusion. CB1 and FAAH mRNA were decreased and increased, respectively, in the basolateral amygdala of TIP39-KO mice. These data suggest that TIP39 signaling modulates nociception, very likely by inhibiting endocannabinoid circuitry at a supraspinal level. We infer a new central mechanism for endocannabinoid regulation, via TIP39 acting on the PTH2R in discrete brain regions.
Collapse
MESH Headings
- Amidohydrolases/metabolism
- Animals
- Cannabinoid Receptor Modulators/metabolism
- Formaldehyde
- In Situ Hybridization
- Injections, Intraventricular
- Injections, Spinal
- Male
- Mice
- Mice, Knockout
- Naloxone/pharmacology
- Narcotic Antagonists/pharmacology
- Neuropeptides/administration & dosage
- Neuropeptides/pharmacology
- Nociceptors/drug effects
- Nociceptors/physiology
- Pain/pathology
- Pain/physiopathology
- Pain Measurement/drug effects
- Piperidines/pharmacology
- Pyrazoles/pharmacology
- RNA, Messenger/biosynthesis
- RNA, Messenger/genetics
- Receptor, Cannabinoid, CB1/antagonists & inhibitors
- Receptor, Cannabinoid, CB1/biosynthesis
- Receptor, Parathyroid Hormone, Type 2/biosynthesis
- Receptor, Parathyroid Hormone, Type 2/genetics
- Rimonabant
- Signal Transduction/physiology
- Stress, Psychological/psychology
- Synapses/physiology
- Vesicular Glutamate Transport Protein 2/biosynthesis
- Vesicular Glutamate Transport Protein 2/genetics
Collapse
Affiliation(s)
- Eugene L Dimitrov
- Section on Fundamental Neuroscience, National Institute of Mental Health, 35 Convent Drive, Room 1B-213, Bethesda, MD 20892, USA.
| | | | | |
Collapse
|
5
|
Arizzi MN, Cervone KM, Aberman JE, Betz A, Liu Q, Lin S, Makriyannis A, Salamone JD. Behavioral effects of inhibition of cannabinoid metabolism: The amidase inhibitor AM374 enhances the suppression of lever pressing produced by exogenously administered anandamide. Life Sci 2004; 74:1001-11. [PMID: 14672756 DOI: 10.1016/j.lfs.2003.07.024] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Biochemical investigations have identified putative enzymatic pathways for the synthesis and metabolism of endogenous cannabinoids. Anandamide amidase is an enzyme that metabolizes anandamide into arachadonic acid and ethanolamine. Using in vitro methods, various inhibitors of amidase have been identified. The present studies were undertaken to determine if the amidase inhibitor AM 374 could enhance the effects of intraperitoneal (IP) injections of anandamide. Three studies were conducted to investigate the effects of various drug treatments on fixed ratio 5 operant lever pressing for food reinforcement. In the first study, the effects of different doses of anandamide were assessed, and it was demonstrated that 5.0 and 10.0 mg/kg anandamide IP significantly suppressed lever pressing, while 2.5 mg/kg produced very little effect. The second study tested the effects of intraventricular (ICV) injections of AM 374, and it was observed that doses up to 10.0, 20.0 and 40 microg AM 374 had no significant effect upon lever pressing. The third study investigated the combined effect of AM374 with a low dose of anandamide. Rats received two drug injections: one ICV and one IP. Four different drug treatments were assessed: 1) ICV vehicle + IP vehicle, 2) ICV vehicle + 2.5 mg/kg anandamide IP, 3) ICV 20.0 microg AM 374 + IP vehicle, and 4) ICV 20 microg AM 374 + 2.5 mg/kg anandamide IP. Combined administration of AM 374 plus anandamide led to a significant decrease in lever pressing compared to either AM374 or anandamide administered alone. Observations of the animals treated with the combination of AM374 plus anandamide indicated that the drug combination resulted in motor slowing, which is consistent with the notion that stimulation of cannabinoid receptors produced a motor deficit that interfered with lever pressing. Although AM374 produced no effect on its own, this amidase inhibitor did enhance the behavioral effect of a low dose of anandamide. These results are consistent with the notion that AM 374 inhibited the enzymatic breakdown of exogenously injected anandamide. This type of procedure can be used to assess a variety of different compounds for their ability to inhibit cannabinoid metabolism.
Collapse
Affiliation(s)
- M N Arizzi
- Department of Psychology, University of Connecticut, Storrs, CT 06269-1020, USA
| | | | | | | | | | | | | | | |
Collapse
|
6
|
Meschler JP, Howlett AC. Signal transduction interactions between CB1 cannabinoid and dopamine receptors in the rat and monkey striatum. Neuropharmacology 2001; 40:918-26. [PMID: 11378162 DOI: 10.1016/s0028-3908(01)00012-0] [Citation(s) in RCA: 81] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Signal transduction interactions between the CB1 cannabinoid and 1 and D2 dopamine receptor systems were studied in rat (Sprague Dawley) and monkey (Macaca fascilaris) striatal membranes. The D2 agonist quinelorane inhibited forskolin (10 microM)-stimulated adenylyl cyclase in a dose-dependent manner (26% and 20% maximal inhibition; EC50 = 2 and 0.5 microM, in rats and monkeys, respectively) and maximal inhibition was completely blocked by the D2 antagonist sulpiride (10 microM). The CB1 agonist desacetyllevonantradol inhibited forskolin-stimulated adenylyl cyclase (18% and 36% maximal inhibition; EC50 = 160 and 73 nM, in rats and monkeys, respectively) and the CB1 antagonist SR141716A (10 microM) completely blocked the maximal inhibition. Combined addition of > EC(90) concentrations of quinelorane (10, 30 microM) and desacetyllevonantradol (1 microM) resulted in no greater inhibition than that produced by either drug alone, indicative of signal transduction convergence between the D2 and CB1 receptor systems. The D1 agonist 6-Br-APB (3-allyl-6-bromo-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepin) produced a dose-dependent stimulation of adenylyl cyclase (45% and 26% stimulation; EC50 = 24 and 32 nM, in rat and monkey, respectively), and maximal stimulation was completely blocked by the D1 antagonist SCH23390 (1 microM). D1 agonist-stimulated activity could be inhibited to basal levels with desacetyllevonantradol (1 microM), indicative of D1 and CB1 signal transduction convergence. The data suggest that CB1 receptors are co-localized with D1 or D2 receptors on the same population of striatal membranes and can interact at the level of G-protein/adenylyl cyclase signal transduction. Similar results obtained with both rat and monkey membranes indicate that striatal dopamine and cannabinoid interactions are conserved for these two species.
Collapse
MESH Headings
- 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine/analogs & derivatives
- 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine/pharmacology
- Adenylyl Cyclases/drug effects
- Adenylyl Cyclases/metabolism
- Analgesics/pharmacology
- Animals
- Corpus Striatum/drug effects
- Corpus Striatum/physiology
- Cyclic AMP/metabolism
- Dopamine Agonists/pharmacology
- Dose-Response Relationship, Drug
- Macaca fascicularis
- Male
- Phenanthridines/pharmacology
- Quinolines/pharmacology
- Rats
- Rats, Sprague-Dawley
- Receptors, Cannabinoid
- Receptors, Dopamine D1/drug effects
- Receptors, Dopamine D1/physiology
- Receptors, Dopamine D2/drug effects
- Receptors, Dopamine D2/physiology
- Receptors, Drug/drug effects
- Receptors, Drug/physiology
- Signal Transduction/drug effects
- Signal Transduction/physiology
- Species Specificity
Collapse
Affiliation(s)
- J P Meschler
- Department of Pharmacological and Physiological Science, Saint Louis University School of Medicine, 1402 South Grand Blvd, St Louis, MO 63104, USA
| | | |
Collapse
|
7
|
Hohmann AG, Tsou K, Walker JM. Cannabinoid suppression of noxious heat-evoked activity in wide dynamic range neurons in the lumbar dorsal horn of the rat. J Neurophysiol 1999; 81:575-83. [PMID: 10036261 DOI: 10.1152/jn.1999.81.2.575] [Citation(s) in RCA: 104] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
The effects of cannabinoid agonists on noxious heat-evoked firing of 62 spinal wide dynamic range (WDR) neurons were examined in urethan-anesthetized rats (1 cell/animal). Noxious thermal stimulation was applied with a Peltier device to the receptive fields in the ipsilateral hindpaw of isolated WDR neurons. To assess the site of action, cannabinoids were administered systemically in intact and spinally transected rats and intraventricularly. Both the aminoalkylindole cannabinoid WIN55,212-2 (125 microg/kg iv) and the bicyclic cannabinoid CP55,940 (125 microg/kg iv) suppressed noxious heat-evoked activity. Responses evoked by mild pressure in nonnociceptive neurons were not altered by CP55,940 (125 microg/kg iv), consistent with previous observations with another cannabinoid agonist, WIN55,212-2. The cannabinoid induced-suppression of noxious heat-evoked activity was blocked by pretreatment with SR141716A (1 mg/kg iv), a competitive antagonist for central cannabinoid CB1 receptors. By contrast, intravenous administration of either vehicle or the receptor-inactive enantiomer WIN55,212-3 (125 microg/kg) failed to alter noxious heat-evoked activity. The suppression of noxious heat-evoked activity induced by WIN55,212-2 in the lumbar dorsal horn of intact animals was markedly attenuated in spinal rats. Moreover, intraventricular administration of WIN55,212-2 suppressed noxious heat-evoked activity in spinal WDR neurons. By contrast, both vehicle and enantiomer were inactive. These findings suggest that cannabinoids selectively modulate the activity of nociceptive neurons in the spinal dorsal horn by actions at CB1 receptors. This modulation represents a suppression of pain neurotransmission because the inhibitory effects are selective for pain-sensitive neurons and are observed with different modalities of noxious stimulation. The data also provide converging lines of evidence for a role for descending antinociceptive mechanisms in cannabinoid modulation of spinal nociceptive processing.
Collapse
Affiliation(s)
- A G Hohmann
- Schrier Research Laboratory, Department of Psychology, Brown University Providence, Rhode Island 02912, USA
| | | | | |
Collapse
|
8
|
Abstract
Although many anecdotal reports indicate that marijuana and its active constituent, delta-9-tetrahydrocannabinol (delta-9-THC), may reduce pain sensation, studies of humans have produced inconsistent results. In animal studies, the apparent pain-suppressing effects of delta-9-THC and other cannabinoid drugs are confounded by motor deficits. Here we show that a brainstem circuit that contributes to the pain-suppressing effects of morphine is also required for the analgesic effects of cannabinoids. Inactivation of the rostral ventromedial medulla (RVM) prevents the analgesia but not the motor deficits produced by systemically administered cannabinoids. Furthermore, cannabinoids produce analgesia by modulating RVM neuronal activity in a manner similar to, but pharmacologically dissociable from, that of morphine. We also show that endogenous cannabinoids tonically regulate pain thresholds in part through the modulation of RVM neuronal activity. These results show that analgesia produced by cannabinoids and opioids involves similar brainstem circuitry and that cannabinoids are indeed centrally acting analgesics with a new mechanism of action.
Collapse
Affiliation(s)
- I D Meng
- Department of Neurology, W. M. Keck Foundation Center for Integrative Neuroscience, University of California, San Francisco 94143-0114, USA.
| | | | | | | |
Collapse
|
9
|
Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: correlation between electrophysiological and antinociceptive effects. J Neurosci 1996. [PMID: 8815936 DOI: 10.1523/jneurosci.16-20-06601.1996] [Citation(s) in RCA: 121] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
The CNS contains a putative cannabinergic neurotransmitter and an abundance of G-protein-coupled cannabinoid receptors. However, little is known about the function of this novel neurochemical system. Cannabinold agonists produce antinociception in behavioral tests, suggesting the possibility that this system serves in part to modulate pain sensitivity. To explore this possibility, the effects of the cannabinoid agonist WIN 55,212-2 on nociceptive neurons in the ventroposterolateral (VPL) nucleus of the thalamus were examined in urethane-anesthetized rats. After identification of a nociresponsive neuron, a computer-controlled device delivered graded pressure stimuli to the contralateral hindpaw. WIN 55,212-2 (0.0625, 0.125, and 0.25 mg/kg, i.v.) suppressed noxious stimulus-evoked activity of VPL neurons in a dose-dependent and reversible manner. Noxious stimulus-evoked firing was affected more than spontaneous firing. These effects were apparently mediated by cannabinoid receptors, because the cannabinoid receptor-inactive enantiomer of the drug (WIN 55,212-3, 0.25 mg/kg) failed to alter the activity of this population of cells. Administration of morphine (0.5 mg/kg, i.v.) produced effects that were very similar to those produced by the cannabinoid. WIN 55,212-2 (0.25 mg/kg, i.v.) failed to alter the responses of non-nociceptive low-threshold mechanosensitive neurons in the VPL WIN 55,212-2 produced antinociceptive effects with a potency and time course similar to that observed in the electrophysiological experiments, despite the differences in the anesthetic states of the animals used in these experiments. The antinociceptive and electrophysiological effects on VPL neurons outlasted the motor effects of the drug. Furthermore, the changes in nociceptive responding could not be attributed to changes in skin temperature. Taken together, these findings suggest that cannabinoids decrease nociceptive neurotransmission at the level of the thalamus and that one function of endogenous cannabinoids may be to modulate pain sensitivity.
Collapse
|
10
|
Prescott WR, Gold LH, Martin BR. Evidence for separate neuronal mechanisms for the discriminative stimulus and catalepsy induced by delta 9-THC in the rat. Psychopharmacology (Berl) 1992; 107:117-24. [PMID: 1317040 DOI: 10.1007/bf02244975] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
The cataleptogenic effect of delta 9-THC was compared to its discriminative stimulus effects in rats. The ED50s for the discriminative stimulus and catalepsy were 0.8 and 4.0 mg/kg, respectively, while their time courses were very similar. The ED50 of delta 9-THC for catalepsy in experimentally naive rats was not different from that in rats trained with the drug discrimination procedure, indicating that the cataleptogenic effect was not appreciably attenuated by long-term exposure to low doses of delta 9-THC. Pharmacologically, the catalepsy produced by delta 9-THC more closely resembled that of haloperidol than of morphine, since anticholinergic pretreatment eliminated the delta 9-THC-induced catalepsy while pre-treatment with naloxone had no effect. Although the cataleptogenic effect of delta 9-THC could be pharmacologically manipulated by anticholinergic pre-treatment, its discriminative stimulus effects were not changed in the same animals. These results demonstrate that distinctive mechanisms of action exist for these cannabinoid-induced behaviors.
Collapse
Affiliation(s)
- W R Prescott
- Department of Pharmacology and Toxicology, Commonwealth of Virginia Drug Abuse Research Center, Virginia Commonwealth University, Richmond 23298
| | | | | |
Collapse
|
11
|
Abstract
The present study demonstrates that desacetyllevonantradol, a synthetic cannabinoid analog, reduces cyclic AMP levels in rat striatal slices stimulated with vasoactive intestinal peptide or SKF 38393, a D1-dopamine agonist. Desacetyllevonantradol and the D2 agonist LY 171555 both inhibited D1-stimulated cyclic AMP accumulation in the striatum. Spiperone, a specific D2-dopamine antagonist, fully reversed the inhibitory effect of LY 171555 but not that of desacetyllevonantradol, indicating that this cannabinoid response is not occurring through a D2-dopaminergic mechanism. Morphine also inhibited cyclic AMP accumulation in striatal slices stimulated with either SKF 38393 or vasoactive intestinal peptide. Naloxone, an opioid antagonist, fully reversed the effect of morphine but not that of desacetyllevonantradol, indicating that cannabinoid drugs are not acting via a mechanism involving opioid receptors. The response to maximally effective concentrations of desacetyllevonantradol was not additive to that of maximally effective concentrations of either morphine or LY 171555, suggesting that dopaminergic, opioid, and cannabinoid receptors may be present on the same populations of cells.
Collapse
Affiliation(s)
- M Bidaut-Russell
- Department of Pharmacological and Physiological Science, Saint Louis University School of Medicine, MO 63104
| | | |
Collapse
|
12
|
Lichtman AH, Martin BR. Cannabinoid-induced antinociception is mediated by a spinal alpha 2-noradrenergic mechanism. Brain Res 1991; 559:309-14. [PMID: 1665384 DOI: 10.1016/0006-8993(91)90017-p] [Citation(s) in RCA: 94] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
The present study examined whether descending noradrenergic and serotonergic systems mediate the antinociceptive effect of the prototypical cannabinoid, delta-9-tetrahydrocannabinol (delta 9-THC). Rats were administered vehicle or delta 9-THC (10 mg/kg, i.v.) and subsequently given an intrathecal (i.t.) injection of either the alpha 2-noradrenergic antagonist yohimbine, or the non-specific serotonin (5-HT) antagonist, methysergide, through chronically implanted spinal catheters. Whereas yohimbine significantly reversed the cannabinoid-induced elevation of tail-flick latencies, methysergide had no effect. To examine whether yohimbine was indeed blocking the antinociceptive effects of delta 9-THC through a spinal mechanism, it was administered i.t. at either the lumbar or the upper thoracic level of the spinal cord. Antinociception was significantly reduced when yohimbine was administered in the lumbar region; however, administration in the upper thoracic region failed to have an effect. In addition, the effect of i.t. administered yohimbine and methysergide was assessed on two other indices sensitive to cannabinoids, hypothermia and ring immobility. As previously reported, i.v. administration of delta 9-THC led to hypothermia as well as immobility in the ring test which were not blocked by i.t. administration of either monoamine antagonist. To the contrary, methysergide potentiated the hypothermic effect of delta 9-THC. These findings indicate that cannabinoids activate descending noradrenergic neurons resulting in antinociception via the stimulation of spinal alpha 2-adrenoceptors.
Collapse
Affiliation(s)
- A H Lichtman
- Department of Pharmacology and Toxicology, Medical College of Virginia, Virginia Commonwealth University, Richmond 23298
| | | |
Collapse
|
13
|
Affiliation(s)
- R G Pertwee
- Department of Pharmacology, Marischal College, University of Aberdeen, Scotland
| |
Collapse
|
14
|
Kataoka Y, Ohta H, Fujiwara M, Oishi R, Ueki S. Noradrenergic involvement in catalepsy induced by delta 9-tetrahydrocannabinol. Neuropharmacology 1987; 26:55-60. [PMID: 3031535 DOI: 10.1016/0028-3908(87)90044-x] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
In order to elucidate the role of the catecholaminergic system in the cataleptogenic effect of delta 9-tetrahydrocannabinol (THC), the effect of pretreatment with 6-hydroxydopamine (6-OHDA) or with desipramine and 6-OHDA and lesions of the locus coeruleus were investigated in rats. The cataleptogenic effect of THC was significantly reduced in rats treated with 6-OHDA and in rats with lesions of the locus coeruleus but not in rats treated with desipramine and 6-OHDA, as compared with control rats. On the contrary, the cataleptogenic effect of haloperidol was significantly reduced in rats treated with desipramine and 6-OHDA but not in rats treated with 6-OHDA or in rats with lesions of the locus coeruleus. These results indicate that noradrenergic neurons have an important role in the manifestation of catalepsy induced by THC, whereas dopaminergic neurons are important in catalepsy induced by haloperidol.
Collapse
|
15
|
Sethi BB, Trivedi JK, Kumar P, Gulati A, Agarwal AK, Sethi N. Antianxiety effect of cannabis: involvement of central benzodiazepine receptors. Biol Psychiatry 1986; 21:3-10. [PMID: 3002503 DOI: 10.1016/0006-3223(86)90003-x] [Citation(s) in RCA: 43] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
The present work, involving clinical, behavioral, and biochemical studies, was undertaken to elucidate the probable mechanism of the observed antianxiety effects of cannabis. The population for the clinical study consisted of 50 male chronic cannabis users who were otherwise healthy and 50 matched controls. When evaluated on Taylor's Manifest Anxiety Scale (TMA), these subjects had low anxiety scores as compared with the controls. To explore the possible interaction of cannabis with the benzodiazepine receptors, behavioral and biochemical studies in mice were devised, involving acute and chronic cannabis administration. Behavioral study revealed that mice under chronic cannabis treatment scored significantly higher on foot shock-induced aggression, but this was significantly blocked by benzodiazepine receptor antagonist. Furthermore, chronic cannabis treatment significantly (p less than 0.001) increased the frequency of licking response periodically punished by shocks. This confirms the antianxiety effect of cannabis, which also appears to be mediated through a benzodiazepine receptor, as it was reduced significantly (p less than 0.001) by a benzodiazepine receptor blocker. Specific 3H-diazepam binding was carried out in frontal cortex to assess both the population and affinity of benzodiazepine receptors. Our results indicate that acute cannabis treatment has no significant effect, whereas chronic cannabis treatment significantly increased 3H-diazepam binding as compared with controls. Scatchard analysis further reveals that increased affinity is responsible for increased binding to these receptors. It is therefore our contention that the antianxiety effect of cannabis is mediated through central benzodiazepine receptors.
Collapse
|
16
|
Arrigo-Reina R, Cosentino C, Reina M, Ferri S. Evidence of an Interaction Between Opioids and Histaminergic Systems on Cannabis Sativa-Induced Catalepsy. Arch Toxicol 1984. [DOI: 10.1007/978-3-642-69132-4_97] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
17
|
Feigenbaum JJ, Yanai J, Moon BH, Klawans HL. Morphine may not produce true catalepsy. Int J Neurosci 1983; 18:199-203. [PMID: 6683262 DOI: 10.3109/00207458308987363] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Though catalepsy is one of the primary features classically associated with morphine injections in animals, several investigators have suggested that morphine may not produce true catalepsy. A study was therefore undertaken using the most widely accepted tests of catalepsy to determine whether a dose related catalepsy could be obtained in rats. The effect produced by morphine was then compared with the catalepsy elicited by subthreshold to suprathreshold doses of haloperidol. In the course of catalepsy assessment, it was found that half the tests employed could not distinguish between the several doses of morphine that were administered. Moreover, the cataleptoid behavior induced by morphine failed to satisfy nearly all of the criteria most widely used for catalepsy. This is in marked contrast to the results obtained with varying doses of haloperidol. These results are compatible with the suggestion that morphine may not be a true cataleptigenic agent.
Collapse
|
18
|
Sharma M, Gujrati VR, Nath C, Bhargava KP, Shanker K. New indolyl peptidyl esters as MAO inhibitors. PHARMACOLOGICAL RESEARCH COMMUNICATIONS 1982; 14:827-37. [PMID: 7178212 DOI: 10.1016/s0031-6989(82)80007-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
|
19
|
Ferri S, Costa G, Murari G, Panico AM, Rapisarda E, Speroni E, Arrigo-Reina R. Investigations on behavioral effects of an extract of Cannabis sativa L. in the rat. Psychopharmacology (Berl) 1981; 75:144-7. [PMID: 6798604 DOI: 10.1007/bf00432176] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
The behavioral responses of the rat to an extract of Cannabis sativa were examined after IP injection of 5, 15 and 30 mg/kg (expressed as delta 9 tetrahydrocannabinol). The lowest dose of the extract induced stereotyped behavior (rhythmic head movements, intermittent gnawing and sniffing) together with hypersensitivity to stimuli and hyperthermia. The administration of higher doses of the extract resulted, initially, in similar behavioral effects but of greater intensity, followed by a cataleptic state alternating with atonic muscular prostration; rectal temperature was decreased. Pre-treatment with 6-hydoxydopamine (6-OHDA, which produces degeneration of catecholamine-containing nerve terminals)or pimozide (blocker of dopamine receptors) significantly reduced both stereotype and hyperreactivity. Thermic effects were also antagonized by 6-OHDA pre-treatment. Cannabis-induced catalepsy was enhanced by pimozide but reduced by atropine (3 mg/kg SC). These results support the hypothesis that catecholamines play an important role in the complex behavioral effects of cannabis.
Collapse
|
20
|
Taylor DA, Fennessy MR. The effect of (-)-trans-delta 9-tetrahydrocannabinol on regional brain levels and subcellular distribution of monoamines in the rat. Clin Exp Pharmacol Physiol 1979; 6:541-8. [PMID: 498594 DOI: 10.1111/j.1440-1681.1979.tb00037.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
1. The effect of intravenously injected delta 9-tetrahydrocannabinol (delta 9-THC, 2 mg/kg) on subcellular distribution in the whole brain and the regional brain levels of noradrenaline, dopamine, serotonin and 5-hydroxyindoleacetic acid were determined in the rat. 2. The levels of noradrenaline and dopamine were not altered by delta 9-THC in the hypothalamic, medullary and rest of brain areas, whereas those of serotonin and 5-hydroxyindoleacetic acid were elevated in the medullary and hypothalalmic areas, respectively. 3. delta 9-THC did not alter the levels of these monoamines and the metabolite 10 min after injection; however, there was a shift of dopamine from the bound to the free fraction. On the other hand, there was a shift of 5-hydroxyindoleacetic acid from the free to the bound fraction. 4. After 1 h, there was no difference in the subcellular ratios of noradrenaline, dopamine, serotonin and 5-hydroxyindoleacetic acid were increased. 5. It is suggested that the effects of delta 9-THC may be mediated by modification of the subcellular distribution of dopamine and serotonin.
Collapse
|
21
|
|